Clinical Trials Logo
  1. Home
  2. Thyroid Cancer
  3. NCT04224792
  4. Details
NCT04224792 Clinical Trial

Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors

Thyroid Cancer Clinical Trial

Official title:
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04224792
Other study ID # 19-008397
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 30, 2022
Est. completion date December 30, 2024

Study information
Verified date June 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are trying to determine whether an exercise program reduces fatigue and improves physical activity in thyroid cancer patients.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults =18yrs of age with well-differentiated thyroid cancer and self-reported fatigue any time after initial treatment of thyroid cancer. - English speaking - Able to provide consent Exclusion Criteria: - Pregnant - Medullary thyroid cancer - Anaplastic thyroid cancer - Physical limitations to perform exercise

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Center-based exercise program
A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
• Home-based exercise program
A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Mayo Clinic

Outcome
Type Measure Description Time frame Safety issue
Primary Fatigue symptoms Change in fatigue symptoms measured using the self-reported Fatigue Symptom Inventory (FSI) survey Baseline, 12 weeks
Primary Physical activity Change in physical activity measured using the self-reported International Physical Activity questionnaire Baseline, 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed NCT01728623 - A Study of E7080 in Subjects With Advanced Thyroid Cancer Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Recruiting NCT05025046 - NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
Not yet recruiting NCT03978351 - The Role of Midkine in Diagnosis of Thyroid Cancer
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Withdrawn NCT01994200 - Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients Phase 1/Phase 2
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00970359 - Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 N/A
Completed NCT00439478 - Dental Safety Profile of High-Dose Radioiodine Therapy Phase 4
Completed NCT00223158 - Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer N/A
Active, not recruiting NCT03246958 - Nivolumab Plus Ipilimumab in Thyroid Cancer Phase 2
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Completed NCT04876287 - Salivary dysfuncTion After Radioiodine Treatment
Recruiting NCT06073223 - Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer N/A
Recruiting NCT06037174 - Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
Recruiting NCT04952493 - Anlotinib or Penpulimab in Combination With RAI for DTC Phase 2

External Links